摘要
目的:研究围手术期应用丹参酮ⅡA磺酸钠对冠心病心绞痛介入治疗患者术后预后产生的影响。方法:以随机数字表法将2013年3月至2017年3月我院收治的94例接受冠状动脉介入术(PCI)冠心病心绞痛病例分为对照组和研究组各47例,对照组在围手术期采用氯吡格雷及阿司匹林等常规疗法,研究组基于常规疗法予以丹参酮ⅡA磺酸钠,比较两组治疗前后血流变、血小板膜糖蛋白、炎性因子与脑尿钠肽(BNP)水平、短期预后及用药不良反应。结果:治疗后,两组血流变各指标水平均显著降低(P<0.05),研究组血液黏度、高/低切全血黏度、血小板最大聚集率以及纤维蛋白原水平显著低于对照组(P<0.05);两组CD62p、CD63、PAC-1、CRP、IL-6、BNP水平明显降低,且CD42b明显增多(P<0.05),研究组CD62p、CD63、PAC-1、CRP、IL-6、BNP水平明显低于对照组(P<0.05);研究组随访时间内心绞痛复发率均明显小于对照组(P<0.05);两组用药不良反应发生率无显著差异(P>0.05)。结论:在冠心病心绞痛患者PCI治疗围手术期应用丹参酮ⅡA磺酸钠,可有效改善患者血流变学相关指标,并产生抗血小板活化效果,促进组织损伤恢复,缓解炎症,提高心功能,且不会增加用药不良反应,短期预后良好。
Objective： To study the effect of application of sodium tanshinone IIA sulfonate in perioperative period on the prognosis of patients with coronary heart disease（ CHD） and angina pectoris after interventional therapy. Methods： 94 cases of CHD with coronary intervention（ PCI） treated by coronary intervention（ PCI） were divided into the control group and the study group with 47 cases each by random number table in March 2013 to March 2017. The control group was treated with conventional therapy such as clopidogrel and aspirin during the perioperative period. The study group was treated with routine treatment with tanshinone IIA A sulfonate. Blood rheology,platelet membrane glycoproteins,inflammatory factors and brain natriuretic peptide（ BNP） levels,short-term prognosis and adverse drug reactions were compared between the two groups before and after treatment. Results： After treatment,the blood rheological indicators were significantly decreased in the two groups（ P〈0.05）,and the blood viscosity,high/low shear blood viscosity,the maximum platelet aggregation rate and fibrinogen levels were significantly lower in the study group than in the control group（ P〈0.05）; the levels of CD62 p,CD63,PAC-1,CRP,IL-6 and BNP were significantly decreased,and CD42 b levels were increased significantly in the two groups（ P〈0.05）,and the above levels in the study group were lower than those in the control group（ P〈0.05）. The recurrence rate of angina pectoris in the study group was significantly lower than that in the control group during follow-up period（ P〈0.05）,and there was no significant difference in the incidence of adverse drug reactions between the two groups（ P〉0.05）. Conclusion： The application of sodium tanshinone IIA sulfonate in perioperative period of PCI can effectively improve the blood rheological indexes,play an antiplatelet role,promote the recovery of tissue injury,relieve inflammation,and improve the cardiac function in patients with coronary heart disease and angina pectoris,without increasing adverse reactions,and the short-term prognosis is good.
作者
朱玉江
邢晓龙
王西辉
ZHU Yujiang et al(The Second Affiliated Hospital of Xi＇an Medical University, Shaanxi Xi＇an 710038, China)
出处
《河北医学》
CAS
2017年第8期1284-1288,共5页
Hebei Medicine
基金
西安医学院校级重点建设学科项目基金陕西省教育厅专项项目基金
(编号:16JK1667)
关键词
围手术期
丹参酮ⅡA磺酸钠
冠心病
心绞痛
Perioperative period
Sodium tanshinone ⅡA sulfonate
Coronary heart disease
Angina pectoris
